Halozyme Therapeutics (HALO) Asset Writedowns and Impairment (2013 - 2020)
Halozyme Therapeutics' (HALO) quarterly Asset Writedowns and Impairment came in at $52000.0 in Q4 2020, down 95.39% year-on-year from $1.1 million in Q1 2020, and down 95.39% on a QoQ basis from $1.1 million in Q4 2019.
Halozyme Therapeutics (HALO) Asset Writedowns and Impairment (2013 - 2020) Analysis & Trends
Halozyme Therapeutics (HALO) has 3 years of Asset Writedowns and Impairment data on file, last reported at $52000.0 in Q4 2020.
- On a quarterly basis, Asset Writedowns and Impairment fell 95.39% year-over-year to $52000.0 in Q4 2020; TTM through Dec 2021 was $1.6 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $48.7 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q4 2020 stood at $52000.0, down from $1.1 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for HALO reached as high as $1.1 million in Q4 2019 and fell as low as $52000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Halozyme Therapeutics | 9.65 Bn | 9.33 Bn | 297.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 52,000.00 |
| Dec 31, 2020 | 52,000.00 |
| Dec 31, 2019 | 1.13 Mn |
| Dec 31, 2019 | 1.13 Mn |
| Mar 31, 2013 | 470,084.00 |
| Mar 31, 2013 | 470,084.00 |